Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis

Bone

Volumn 30, Issue 5 SUPPL. 1, 2002, Pages 75-79

  Body, J J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Bone mass; Bone mineral density; Calcitonin; Fracture; Osteopenia; Osteoporosis

Indexed keywords

CALCITONIN; CALCITONIN RECEPTOR; CALCIUM; VITAMIN D;

ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MASS; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LONG TERM CARE; LUMBAR SPINE; POSTMENOPAUSE OSTEOPOROSIS; PROPHYLAXIS; RISK FACTOR; TRABECULAR BONE; VERTEBRA FRACTURE;

EID: 0036241632     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(02)00715-9     Document Type: Article

References (42)

1. Salmon calcitonin in the prevention of bone loss at perimenopause
2. Regulation of lymphocyte calcitonin receptors by interleukin-1 and interleukin-6
3. Calcitonin receptors on circulating normal human lymphocytes
4. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study
5. Bone turnover in postmenopausal osteoporosis: Effect of calcitonin treatment
6. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial
7. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis
8. Calcitonin increases the concentration of insulin-like growth factors in serum-free cultures of human osteoblast-line cells
9. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss
10. Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis
11. Clinical significance of antibodies against calcitonin
12. Long-term calcitonin therapy in postmenopausal osteoporosis
13. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture
14. Effect of calcitonin on vertebral and other fractures
15. The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: Evidence of maximal effect after 8 weeks of continuous treatment
16. Synthetic human calcitonin in postmenopausal osteoporosis: A placebo-controlled, double-blind study
17. Prevention of bone loss in early nonsurgical and nonosteoporotic high turnover patients with salmon calcitonin: The role of biochemical bone markers in monitoring high turnover patients under calcitonin treatment
18. Effects of salmon calcitonin in postmenopausal osteoporosis: A controlled double-blind clinical study
19. Effects of salmon calcitonin on the bone loss induced by ovariectomy
20. A clinical trial on the effects of a combination of Elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women
21. Dose-effect on bone density and parathyroid function of intranasal salmon calcitonin when administered without calcium in postmenopausal women
22. Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women
23. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study
24. Discontinuous calcitonin treatment of established osteoporosis: Effects of withdrawal of treatment
25. Effect of salcatonin given intranasally on early postmenopausal bone loss
26. Nasal calcitonin for treatment of established osteoporosis
27. Endogenous production of specific antibodies does not decrease hypocalcemic response to calcitonin in young rabbits
28. 1-year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin
29. Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (i.m.) or placebo injection in normal subjects
30. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent salmon calcitonin
31. Relationship between whole plasma calcitonin levels, calcitonin secretory capacity, and plasma levels of estrone in healthy women and postmenopausal osteoporotics
32. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss
33. Prevention of osteoporosis with nasal salmon calcitonin: Effect of anti-salmon calcitonin antibody formation
34. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium
35. Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome
36. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: A prospective study
37. Ergebnisse einer kontrollierten einjähringen Behand-lung der primären Osteoporose mit Calcium und Lachscalcitonin
38. Morning or evening administration of nasal calcitonin? Effects on biochemical markers of bone turnover
39. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis
40. Acute effects of nasal salmon calcitonin on calcium and bone metabolism
41. Effect of different doses of nasal salmon calcitonin on bone mass
42. Long- and short-term side effects and safety of calcitonin in man: A prospective study